Co-founder & CTO at FinalDose | PhD of Oxford compbio
Joined April 2026
- Tweets14
- Following112
- Followers89
- Likes164
Steven Lin retweeted
FinalDose: We’re going to end cancer in the open
We plan to build FinalDose as public as we possibly can and write up as we go, including the parts that don’t survive! Please help spread the word:
@FinalDoseLFG
substack.com/@finaldose
Steven Lin retweeted
Please follow us! We're ending cancer 😇
finaldose.substack.com/p/fin…
Steven Lin retweeted
substack.com/@finaldose/note…
We're going to be the first company to end cancer in the open!
Brilliant protein designer and awesome founder. Would recommend!
We are Hiring!
Definitely work well together if:
>you're an overachiever
> chill
> agentic systems in bio sound intriguing.
>based in SF @fdotinc
DMs are open!
If you know anyone, reach out!
Steven Lin retweeted
🚨 Founding Engineer @ Proteus Bio: Building frontier biological intelligence.
> Autonomy: high
> ML/RL
> Bio knowledge ideal
> Interview: pub
> Education: don’t care
> Mindset: here to leave the world better than you found it
DM me.
🤤🤤🤤
Protenix-v2 weights available now😍
apples to apples comparison from Lucas Nivon post. Protenix ahead of all; AF3, Boltz, OF3-p2 on a blind test set of protein/ligand. So for Co-Folding use minimum Protenix-v2
huggingface.co/TMF001/proten…
Awesome human doing awesome stuff
Thrilled to share our new preprint from the Doudna Lab!
“Undruggable” cancer mutations remain very hard to target with current modalities. What if we could instead sense mutant transcripts and convert that recognition into selective cell killing?
biorxiv.org/content/10.64898…
Steven Lin retweeted
Our biggest breakthrough in efficiency yet, the Framework Laptop 13 Pro with 20 hours of battery life. In Graphite.
Linux-first with options for Ubuntu pre-installed. Featuring Intel® Core™ Ultra Series 3 processors, LPCAMM2 Memory, a new haptic touchpad, and a touchscreen display.
Pre-orders for the Framework Laptop 13 Pro open now: frame.work
Hot take: rather than using frontier protein models to accelerate designing a new drug for every disease, use them to perfect ONE programmable drug. Delivery is unsolved, it's early. But the ceiling - collapsing the $2B/decade drug R&D, is too high not to take a chance on.
